A few days ago, by the National Center for Cardiovascular Diseases, the Chinese Medical Association, the Chinese Medical Association Division of Cardiovascular Diseases and other academic institutions *** with the development of the "Chinese hypertension clinical practice guidelines" (hereinafter referred to as the "Guidelines") was formally promulgated,which, it is worth noting that the new guidelines will be the diagnostic criteria for hypertension by ≥140/90mmHg down to ≥130/80mmHg. 80mmHg.
In contrast to the lowering of the hypertension threshold, the number of patients with hypertension will also increase significantly. According to a forecast by Yingxian Sun, director of the cardiovascular medicine department at the First Affiliated Hospital of China Medical University, the number of Chinese adults with high blood pressure is estimated to reach 613 million based on the new standard, while the number of people who meet the 140/90mmHg standard is about 268 million. This means that under the new standard, there will be more than 300 million new hypertensive patients in China.
For the data of the downward adjustment, a number of experts said, No need to "talk about the disease", the intention is to prevent and control the port forward, so that more people in the past "normal high value" people to be diagnosed, earlier! The goal is to make more people with normal high blood pressure diagnosed with a higher risk of developing cardiovascular disease and death by providing them with earlier blood pressure monitoring, medication, and long-term management.
Guide development team experts, Hebei Provincial People's Hospital Vice President Guo Yifang also explained in an interview with the media, "so that in 5-10 years, cardiovascular and cerebrovascular disease can be reduced to save a lot of medical costs, a small portion of the people who take the medicine will pay the economic cost of far less than these medical costs. "
In terms of blood pressure testing and antihypertensive medication, the Guidelines also give appropriate advice, among which, in terms of blood pressure testing, it is recommended that adults use standardized and validated electronic sphygmomanometers to measure their blood pressure, and that home self-testing of blood pressure is preferred in efficacy assessment and follow-up.
Compared with traditional sphygmomanometers, electronic sphygmomanometers are a kind of medical devices that use modern electronic technology and the principle of indirect measurement of blood pressure for blood pressure measurement, which has the advantages of non-pollution, easy to operate, simultaneous measurement of multiple parts, and data preservation, which is easier to be used in the family.
But the popularity of domestic electronic blood pressure is not high. From the current market point of view, the United States, Japan's home electronic blood pressure monitor penetration rate of 50%, 60%, respectively, while China's penetration rate is only 1.2%.
However, the domestic household medical equipment leading Yuyue medical had said in this year's semiannual report, although our country compared with developed countries is still a small gap, but in recent years, with the prevalence of hypertension in China and blood pressure detection awareness continues to improve, the market demand is also further catalyzed, the relevant business prospects are broad.
With the arrival of the post-epidemic era, a number of research reports also pointed out that the localization of the medical device industry, the internationalization process will also be further accelerated. At present, in addition to the fish leap medical, canfu medical, nine Ann medical, music heart medical products are involved in blood pressure meter.
Corfu medical said, the company's existing products are rich in health monitoring, rehabilitation aids and other five series, has been iteratively launched, such as electric wheelchairs, blood pressure monitors and other high-quality best-selling products, has accumulated a good market reputation and brand awareness.
As of the close of the lunch market, the fish leap medical 10CM stop, canfu medical, music heart medical rose 13.66% and 7.66% respectively.
In addition to the expansion of the demand for sphygmomanometers, diagnostic standards adjusted drug group expansion, does it also mean that the antihypertensive drug market expansion?
According to China Business Intelligence Network data statistics show that under the diagnostic standard of 140/90mmHg, China's anti-hypertensive drug market sales scale is growing steadily, China's anti-hypertensive drug market size of about 95.6 billion yuan in 2020, an increase of 8% year-on-year, the market size will continue to expand in the future, but the rate of growth will be slowed down, and is expected to be in 2022 China's anti-hypertensive drug market size will reach 103.5 billion yuan.
A number of experts analyzed that under the diagnostic standard adjustment, the overall medication does have a small increase. According to the "Guide" initiated and chair expert, National Cardiovascular Disease Center/Chinese Academy of Medical Sciences outside the hospital professor Cai Jun, the new group of drugs is expected to be in the 40 million, the overall amount of drugs probable increase of 5%.
It is understood that antihypertensive drugs are mainly calcium antagonists, renin-angiotensin-aldosterone system inhibitors, adrenergic receptor blockers, compound antihypertensive drugs, diuretics and so on.
It is worth noting that the Guidelines also give certain medication recommendations, including the recommendation of initial treatment, i.e., combination of drugs, with preference given to single-tablet combinations (ACEI/ARB + CCB or ACEI/ARB + diuretics).
Compound antihypertensive drugs better compliance, convenience and other advantages by the market favor, so that the market in recent years the growth rate is obvious. Data show that the market size of compound antihypertensive drugs in 2018 was about 10.36 billion yuan, an increase of 4.1% year-on-year, with a faster growth rate, and it is expected that the market size of compound antihypertensive drugs will reach 21.09 billion yuan in 2030, which will become the second largest class of antihypertensive drugs.
Merchants Securities said that with the national collection and procurement, the penetration rate of hypertension drugs is rapidly increasing. In the future, with relatively few heavyweight new drugs, the market should be able to maintain an annual growth rate of about 2% as aging deepens.
According to the incomplete statistics of the Science and Technology Board Daily, A-share related companies include:
Related reportsDiagnostic standard adjustment "woke up overnight" in China added more than 300 million hypertensive patients?